{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:16Z","timestamp":1792123096830,"version":"4.4.0"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,10,2]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>There is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess their efficacy and safety in this setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the Club Rhumatismes and Inflammation French network, we conducted a multicentre, retrospective, observational study of patients with cancer diagnosed with inflammatory arthritis under ICI(s) and treated with bDMARD or JAKi. Clinical data were collected using a standardised case report form.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty patients (60% men, median age 69.5 years) were included, with rheumatoid arthritis (RA)-like (n=16), polymyalgia rheumatica-like (n=2) or psoriatic arthritis-like (n=2) clinical presentation. Two patients had pre-existing RA. 90% were treated with glucocorticoids as first-line therapy and 60% received methotrexate prior to bDMARD or JAKi. Anti-interleukin-6 receptor (IL-6R) therapy was used in 13\/20 patients (65%), leading to clinical improvement in 11\/13 patients (85%), but one patient experienced intestinal perforation and cancer progression was noticed in 6\/13 patients (46%). Tumour necrosis factor inhibitors were used in 5\/20 patients (25%), with improvement in 4\/5 patients (80%) and cancer progression was observed in 3\/5 patients (60%). Two infections (diverticulitis and pneumonitis) were reported. Anakinra, baricitinib and ustekinumab were each used in one patient. Median duration of the bDMARD or JAKi was 17 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Anti-IL-6R therapy is currently the most common strategy in patients with ICI-induced inflammatory arthritis and insufficient response to glucocorticoids and methotrexate, leading to improvement in &gt;80%. Overall, cancer progression occurred in about half of patients and whether the bDMARD\/JAKi impacted the tumour response remains to be determined.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002612","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T09:57:43Z","timestamp":1666346263000},"page":"e002612","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03999749","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fanny","family":"De La Fuente","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakiba","family":"Belkhir","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Bicetre, Assistance Publique-H\u00f4pitaux de Paris, FHU CARE, Le Kremlin-Bicetre, France"},{"name":"Inserm UMR 1184, Universite Paris-Saclay Faculte de Medecine, Le Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Bicetre, Assistance Publique-H\u00f4pitaux de Paris, FHU CARE, Le Kremlin-Bicetre, France"},{"name":"Inserm UMR 1184, Universite Paris-Saclay Faculte de Medecine, Le Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Duc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier de Bethune, Bethune, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-0983","authenticated-orcid":false,"given":"Thao","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sainte-Marguerite Hospital, Assistance Publique - H\u00f4pitaux de Marseille, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Germain","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier de Pau, Pau, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Edouard","family":"Gavand","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Clinique Rhena, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Labadie","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Briere","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Intercommunal de Creteil, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambre","family":"Lauret","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Intercommunal de Creteil, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Cardon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Lille University Hospital Center, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Mouterde","sequence":"additional","affiliation":[{"name":"Departement of Rheumatology, Lapeyronie Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Bicetre, Assistance Publique-H\u00f4pitaux de Paris, FHU CARE, Le Kremlin-Bicetre, France"},{"name":"Inserm UMR 1184, Universite Paris-Saclay Faculte de Medecine, Le Kremlin-Bicetre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Rouxel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Arcachon Hospital, La Teste de Buch, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8045-0180","authenticated-orcid":false,"given":"Marie-Elise","family":"Truchetet","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3029-8739","authenticated-orcid":false,"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-6200","authenticated-orcid":false,"given":"Marie","family":"Kostine","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2025090313212029000_8.2.e002612.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025090313212029000_8.2.e002612.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257"},{"key":"2025090313212029000_8.2.e002612.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9"},{"key":"2025090313212029000_8.2.e002612.4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000906"},{"key":"2025090313212029000_8.2.e002612.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139"},{"key":"2025090313212029000_8.2.e002612.6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435"},{"key":"2025090313212029000_8.2.e002612.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025090313212029000_8.2.e002612.8","unstructured":"Calabrese C , Esfahani K , Calabrese L . Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers [abstract]. Arthritis Rheumatol 2021;73 https:\/\/acrabstracts.org\/abstract\/concomitant-targeted-therapy-with-ongoing-immune-checkpoint-inhibitor-ici-therapy-for-severe-immune-related-adverse-events-iraes-clinical-experience-from-two-centers\/"},{"key":"2025090313212029000_8.2.e002612.9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0711-0"},{"key":"2025090313212029000_8.2.e002612.10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000268","article-title":"Incidence and clinical impact of Anti-TNF\u03b1 treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J Immunother"},{"key":"2025090313212029000_8.2.e002612.11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003277"},{"key":"2025090313212029000_8.2.e002612.12","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144"},{"key":"2025090313212029000_8.2.e002612.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211560"},{"key":"2025090313212029000_8.2.e002612.14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025090313212029000_8.2.e002612.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"2025090313212029000_8.2.e002612.16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"key":"2025090313212029000_8.2.e002612.17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003551"},{"key":"2025090313212029000_8.2.e002612.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"2025090313212029000_8.2.e002612.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02358-7"},{"key":"2025090313212029000_8.2.e002612.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3449"},{"key":"2025090313212029000_8.2.e002612.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004"},{"key":"2025090313212029000_8.2.e002612.22","doi-asserted-by":"crossref","first-page":"S869","DOI":"10.1016\/j.annonc.2021.08.1425","article-title":"1040O phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma","volume":"32","author":"Weber","year":"2021","journal-title":"Ann Oncol"},{"key":"2025090313212029000_8.2.e002612.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"2025090313212029000_8.2.e002612.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2025090313212029000_8.2.e002612.25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32080"},{"key":"2025090313212029000_8.2.e002612.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2025090313212029000_8.2.e002612.27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000714"},{"key":"2025090313212029000_8.2.e002612.28","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090313212029000_8.2.e002612.29","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/rheumatology\/key234","article-title":"High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis","volume":"57","author":"Ford","year":"2018","journal-title":"Rheumatology"},{"key":"2025090313212029000_8.2.e002612.30","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10067-020-05420-w","article-title":"Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?","volume":"40","author":"Chatzidionysiou","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025090313212029000_8.2.e002612.31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:21:28Z","timestamp":1756930888000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/rmdopen-2022-002612"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002612","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}